Hiring in life sciences? Share your open positions with our professional community. Read more Close

Image

A Rare Look into New Guidances: The Future State of Orphan Drug Development

Webinar Posted on 03 Feb 2025

Speaker

Adam Bloomfield, Leslie Wetherell, Paulla Dennis

When and where

Starts: Tuesday, 25 February 2025 - 11:00
Ends: Tuesday, 25 February 2025 - 12:00
Location: Xtalks, Toronto, Canada
Location details: Free Registration on Xtalks.com

Event description

Rare disease drug development is evolving, driven by innovation and regulatory advancements. With many devastating rare diseases still lacking approved treatments, regulatory agencies are taking significant steps to support innovators, advance research and improve patient outcomes. Through updated and newly developed guidances, they aim to provide a roadmap for navigating the complexities of this specialized field.

In this webinar, they will highlight key regulatory guidances published within the past year, addressing artificial intelligence (AI), accelerated approval pathways and fostering diversity, equity and inclusion (DEI) in clinical research. Attendees will gain insights into the challenges these guidances aim to address, their potential to transform the rare disease landscape, and strategies for incorporating any necessary changes into drug development programs.

Register for this webinar to explore how the rare disease landscape is changing with guidance from AI, accelerated approval pathways and fostering DEI in clinical research.

Further details

IMPORTANT: In order to register to this free webinar you must register directly on Xtalks via the following URL: https://xtalks.com/webinars/a-rare-look-into-new-guidances-the-future-state-of-orphan-drug-development/

Geolocation will be visible after you sign in.

Advertisement

Stats

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 119
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement